OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

OBB RSS Feed

  •  

Event Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2014

« Federal Circuit Affirms Summary Judgment of No DOE Infringement in CENESTIN Case | Main | ACI "Maximizing Pharmaceutical Patent Lifecycles" Conference, New York, October 4-5 »

July 31, 2011

Comments

patent litigation

Although a bit of trepidation is likely in order (no matter on what end of the spectrum you tend to fall), I look forward to reading what the SCOTUS has to say when the esteemed Justices opine on gene patents. Particularly since Myriad presents a bit of a chicken-and-egg question -- that is thus perhaps not scientifically, definitively solvable -- policy considerations will probably weigh heavily in their ultimate determination. Which also makes one wonder to what extent the Court's new political makeup will affect the case's outcome.
http://www.GeneralPatent.com/blog/

The comments to this entry are closed.